LONDON — I’m always searching for shares that can help ordinary investors like you make money from the stock market. However, many people are currently worried the market could be overheating.
So right now I’m analyzing some of the most popular companies in the FTSE 100, hoping to establish if they can continue to outperform in today’s uncertain economy.
Today, I’m looking at drinks giant Diageo (LSE: DGE ) (NYSE: DEO ) to determine whether the shares are still safe to buy at 1,905 pence.
So, how’s business going?
Diageo has been going from strength to strength recently as a combination of organic growth and bolt-on acquisitions have enabled the company to improve earnings by nearly 40% in just three years.
However, there could be some speed bumps ahead for Diageo as the company faces new, strict government regulation in one of its key growth markets: Turkey.
In particular, the Turkish government recently voted into law a bill that prohibits the sale of alcoholic beverages at night and bans the advertisement of alcohol, which could put the brakes on Diageo’s growing sales in the country.
Top 5 Safest Stocks To Own For 2015: Immune Design Corp (IMDZ)
Immune Design Corp, incorporated on February 20, 2008, is a clinical-stage immunotherapy company. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs), to fight cancer. The Company is developing multiple product candidates from its two discovery platforms, DCVex and GLAAS. The Company’s product candidates, LV305, CMB305 and G100, utilize multiple immuno-oncology approaches. LV305 was developed from the DCVex platform and it is enrolling patients in a Phase I clinical trial for the treatment of five solid tumor types. CMB305 is a prime-boost approach that combines LV305 with a second agent, G305. G100 was developed from the GLAAS platform and it is enrolling patients with Merkel cell carcinoma in a Phase I clinical trial.
The Company’s immuno-oncology product candidates are being developed in two separate approaches: Specific Antigen and Endogenous Antigen. The Specif ic Antigen approach uses selected antigens that are also present in the patient’s tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen. The Endogenous Antigen approach, in contrast, does not require a selected antigen present in the tumor. It instead relies on treatments, such as chemotherapy or local radiation to lyse tumors and release endogenous antigens, which are then captured by neighboring GLAAS-activated dendritic cells, generating a varied immune response. The Company utilizes DCVex and GLAAS to develop product candidates that work in vivo and are designed to create and expand diverse armies of CTLs to fight tumors. DCVex is a discovery platform that uses a first-in-class vector to generate product candidates designed to create CTLs in vivo. The DCVex vector is a delivery system based on a re-engineered virus to carry the genetic information of a tumor antigen safely and selectively to dendriti c cells (DCs), in the skin. The GLAAS platform also works in! vivo and is based on a small synthetic molecule called GLA, which stands for glucopyranosyl lipid A. GLA selectively binds to the TLR4 receptor and causes potent activation of the DC.
- [By WWW.DAILYFINANCE.COM]
www.gopro.com Now that it’s nearly over, we can definitively say that 2014 has been one of the best years for initial public stock offerings in history. In terms of proceeds raised from IPOs, 2014 will challenge or even exceed the year 2000. Which is saying something: That was the height of the dot.com frenzy, when seemingly every new company with a website felt compelled to list on the stock exchange. As can be expected of a busy IPO year, some of 2014’s new stock market titles have been runaway hits soaring above their issue price, while others have belly-flopped. Since we’re heading into the most optimistic time of the year, we’ll shine a light on the three best performers. In order of stock price appreciation, they are: GoPro (GPRO) 2014’s current IPO front-runner is this company, maker of the popular action photography camera — the one that’s usually responsible for those hairy point-of-view videos posted on Facebook (FB) and other online sharing sites. GoPro’s stock hit the market at the end of June priced at $24, and as if this writing it now stands at $70.72 for a muscular 195 percent total return. Although that’s impressive, it should be noted that the current price is quite a bit lower than the stock’s high of nearly $94, which it touched in early October. But then the camera was effectively blamed for the horrific accident that befell Formula One racing star Michael Schumacher — although the journalist making the allegation later recanted — and the shares cratered. The stock recovered after the company reported strong third-quarter earnings, and all seemed well again… until GoPro decided to float a secondary issue of stock. It’ll sell 10.3 million fresh shares on the market, adding to the nearly 126 million currently outstanding. When secondary share issues are announced, a company’s stock often takes a hit, since investors aren’t too crazy about their existing stakes being diluted. Regardless, on a fundamental basis GoPro is a popular, if
Top 5 Safest Stocks To Own For 2015: CEL-SCI Corp (CVM)
CEL-SCI Corporation (CEL-SCI), incorporated on March 22, 1983, is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine.
CEL-SCI’s Multikine, is being developed for the treatment of cancer. It is a cancer immunotherapy drugs called Combination Immunotherapy because it combines active and passive immunity in one product. It is the only cancer immunotherapy that both kills cancer cells and activates the general immune system to destroy the cancer. Multikine target the tumor micro-metastases for treatment failure. Multikine is also applicable in many other solid tumors.
New Manufacturing Facility
CEL-SCI’s facility manufactures Multikine for CEL-SCI’s Phase III clinical trial. CEL-SCI offers the use of the facility as a service to pharmaceutical companies and others, particularly those that need to fill and finish their drugs in a cold environment. Fill and finish is the process of filling injectable drugs in a sterile manner.
CEL-SCI’s patented T-cell Modulation Process uses heteroconjugates to direct the body to choose a specific immune response. The heteroconjugate technology, referred to as LEAPS, is intended to stimulate the human immune system to fight bacterial, viral and parasitic infections, as well as autoimmune, allergies, transplantation rejection and cancer. Administered like vaccines, LEAPS combines T-cell binding ligands with small, disease associated and peptide antigens.
Using the LEAPS technology, CEL-SCI has created a peptide treatment for H1N1 (swine flu) hospitalized patients. This LEAPS flu treatment is designe d to focus on the conserved, non-changing epitopes of the di! fferent strains of Type A Influenza viruses, including swine, avian or bird, and Spanish Influenza. CEL-SCI’s LEAPS flu treatment contains epitopes.
- [By James E. Brumley]
Little TNI Biotech Inc. (OTCMKTS:TNIB) just gave bigger immunology players like Amgen, Inc. (NASDAQ:AMGN) or CEL-SCI Corporation (NYSEMKT:CVM) a new reason to worry. Though CVM and AMGN aren’t exactly sweating bullets yet, TNIB has taken not a big step forward in terms biotechnological progress, but rather, has widened its net with a lateral expansion.
- [By Bryan Murphy]
It may not have blazed a trail into the young, immunology segment of the biotech industry the way Dendreon Corporation (NASDAQ:DNDN) did back in 2010 with the debut of Provenge. It may not have the same immunology pipeline (and company size) that ImmunoGen, Inc. (NASDAQ:IMGN) boasts. One thing is pretty certain about cancer-immunotherapy developer CEL-SCI Corporation (NYSEMKT:CVM) right now, however – its stock may be poised to dole out a much bigger foreseeable-future reward than DNDN or IMGN are.
- [By Bryan Murphy]
Look out AbbVie Inc. (NYSE:ABBV), and Gilead Sciences, Inc. (NASDAQ:GILD), you may want to look over your shoulder as well. There’s a new immunology player coming to town, and its name is CEL-SCI Corporation (NYSEMKT:CVM). Yes, AbbVie may be the name behind blockbuster drug Humira – with nearly $10 billion in sales in 2012 – while Gilead Sciences is saving HIV patients’ lives with immunological therapies Stribild and Complera. But, small cap company CEL-SCI may be closer to launching its own immunology drug sooner than most investors realize.
Top 5 Safest Stocks To Own For 2015: EverBank Financial Corp (EVER)
EverBank Financial Corp, incorporated in 2004, is an unitary savings and loan holding company. The Company provides a range of financial products and services directly to customers through multiple business channels. Its operating subsidiary is EverBank. As of December 31, 2011, EverBank had $ 10.3 billion deposits. EverBank offers a range of banking, lending and investing products to consumers and businesses. EverBank provides services to customers through Websites, over the phone, through the mail and at 14 Florida-based Financial Centers. The Company operates in two operating business segments: Banking and Wealth Management, and Mortgage Banking. Its Banking and Wealth Management segment includes earnings generated by and activities related to deposit and investment products and services and portfolio lending and leasing activities. Its Mortgage Banking segment consists of activities related to the origination and servicing of residential mortgage loans. In April 2012, the Company acquired MetLife Bank’s warehouse finance business. In October 2012, it acquired Business Property Lending, Inc.
Asset Origination and Fee Income Businesses
The Company has a range of asset origination and fee income businesses. The Company generates generate fee income from its mortgage banking activities, which consist of originating and servicing one-to-four family residential mortgage loans. It originates prime residential mortgage loans using a centrally controlled underwriting, processing and fulfillment infrastructure through financial intermediaries (including community banks, credit unions, mortgage bankers and brokers), consumer direct channels and financial centers. Its mortgage origination activities include originating, underwriting, closing, warehousing and selling to investors prime conforming and jumbo residential mortgage loans. From its mortgage origination activities, it earns fee-based income on fees charged to borr owers and other noninterest income from gains on sales from ! mortgage loans and servicing rights. During the year ended December 31, 2011, it originated six billion dollars of residential loans. It generates mortgage servicing business through the retention of servicing from its origination activities, acquisition of bulk mortgage servicing rights (MSR) and related servicing activities.
The Company’s mortgage servicing business includes collecting loan payments, remitting principal and interest payments to investors, managing escrow funds for the payment of mortgage-related expenses, such as taxes and insurance, responding to customer inquiries, counseling delinquent mortgagors, supervising foreclosures and liquidations of foreclosure properties and otherwise administering its mortgage loan servicing portfolio. It earns mortgage servicing fees and other ancillary fee-based income in connection with these activities. It services a portfolio by both product and investor, including agency and private pools of mortgages se cured by properties throughout the United States. As of December 31, 2011, its mortgage servicing business, which services mortgage loans for itself and others, managed loan servicing administrative functions for loans with unpaid principal balance (UPB) of $54.8 billion.
The Company originates originate equipment leases nationwide through relationships with approximately 280 equipment vendors with networks of creditworthy borrowers and provide asset-backed loan facilities to other leasing companies. Its equipment leases and loans finance essential-use health care, office product, technology and other equipment. Its commercial financings range from approximately $25,000 to $1.0 million per transaction, with typical lease terms ranging from 36 to 60 months. Its commercial finance activities provide it with access to approximately 25,000 small business customers nationwide, which creates opportunities to cross-sell its deposit, lending and wealth management produc ts. It focuses to offer warehouse loans, which are short-ter! m revolvi! ng facilities, primarily securitized by agency and government collateral. It provides financial advisory, planning, brokerage, trust and other wealth management services to its mass-affluent and high-net-worth customers through its registered broker dealer and recently-formed registered investment advisor subsidiaries.
Interest-Earning Asset Portfolio
As of December 31, 2011, the Company’s interest-earning assets were $11.7 billion. As of December 31, 2011, its loan and lease held for investment portfolio was $6.5 billion. As of December 31, 2011, the carrying values of its interest-earning assets are: residential, government-insured (residential), securities, commercial and commercial real estate, Bank of Florida (covered), lease financing receivables, and other.
Residential includes primarily prime loans originated and retained from its mortgage banking activities, acquired from third parties or held for sale to other investors. go vernment-insured (residential) includes Government National Mortgage Association (GNMA) pool buyouts with government insurance, sourced from its mortgage banking segment and third-party sources. Securities include non-agency residential mortgage-backed securities (MBS) and collateralized mortgage obligation (CMO) purchased at significant discounts. This portfolio includes protection against credit losses from purchase discounts, subordination in the securities structures and borrower equity. Commercial and commercial real estate includes a range of commercial loans, including owner-occupied commercial real estate, commercial investment property and small business commercial loans. As of December 31, 2011, Bank of Florida (Covered) includes commercial, multi-family and commercial real estate loans with $71.3 million of purchase discounts. Lease financing receivables include covered lease financing receivables. As of December 31, 2011, the lease portfolio had $64.7 million of total discounts. Other includes home equity loans and lines ! of credit! , consumer and credit card loans and other investments.
As of December 31, 2011, the Company had approximately $10.3 billion in deposits. Its market-based deposit products, consisting of its WorldCurrency, MarketSafe and EverBank Metals Select products, provide investment capabilities for customers seeking portfolio diversification with respect to foreign currencies, commodities and other indices. Its financial portal includes online bill-pay, account aggregation, direct deposit, single sign-on for all customer accounts and other features. Its Website and mobile device applications provide information on its product offerings, financial tools and calculators, newsletters, financial reporting services and other applications for customers to interact with it and manages all of their EverBank accounts on a single integrated platform. Its new mobile applications allow customers using iPhone, iPad, Android and Blackberry devices to vie w account balances, conduct real time balance transfers between EverBank accounts, administer billpay, review account activity detail and remotely deposit checks.
The Company generates deposit customer relationships through its consumer direct, financial center and financial intermediary distribution channels. Its consumer direct channel includes Internet, e-mail, telephone and mobile device access to product and customer support offerings. Its direct distribution with a network of 14 financial centers in Florida metropolitan areas, include Jacksonville, Naples, Ft. Myers, Miami, Ft. Lauderdale, Tampa Bay and Clearwater. As of December 31, 2011, its financial centers had average deposits of $130.5 million, which is approximately double the industry average. In addition, it generates noninterest-bearing escrow deposits from its mortgage servicing business.
- [By Nicole Seghetti]
3. Build your savings account
Take this opportunity to bolster your savings such that you have at least three months’ worth of living expenses socked away. Money market or savings accounts will provide you with the best rates. For example, American Express’ (NYSE: AXP ) high-yield savings account pays 0.85%, and Capital One Financial’s (NYSE: COF ) Capital One 360 offers a 0.75% APY. Both accounts boast no minimum balances and no fees. Meanwhile, EverBank Financial (NYSE: EVER ) pays an attractive 1.01% money market rate but requires a $1,500 minimum opening balance.
Top 5 Safest Stocks To Own For 2015: Fidia SpA (FDA)
Fidia SpA is an Italy-based company primarily engaged in the production of numerical controls and machine tools. The Company’s activities are divided into three main business lines. In the High-speed Milling Systems, it is involved in the production and sale of milling heads kits and cutting-edge equipment. Through the Numerical Controls, Dives and Software sector, it is active in the manufacture of numerical controls for milling systems, as well as in the development and distribution of computer-aided design (CAD) and computer-aided manufacturing (CAM) software. The After-sales Service sector includes the provision of technical services, sale of spare parts and scheduled maintenance contracts. The Company operates in Germany, France, Brazil, China, Poland and India, among others. Advisors’ Opinion:
- [By Rahul Chattaraj]
Every year more and more people are becoming health conscious and healthcare is one such industry which I feel can never be in slump. It’s is just brilliant of Apple to embed a hardware in a smartphone which will be able to cash on this opportunity. The iPhone 5S already has the hardware components to support the Healthbook app and once the iOS 8 is released for the next iPhone model and upgrades are available for the iPhone 5S, Apple will be poised to see huge surge in the demand for its devices. Certain incidents such as the top Apple executives meeting the US Food and Drug Administration (FDA), and former Mashimo Corp. Chief Medical Officer Michael O’Reilly joining Apple are clearly hinting that the company’s mobile health dreams will very soon turn into reality.
- [By Patricio Kehoe]
Despite recent anti-tobacco laws passed by the European Union and the Food and Drug Administration (FDA) in the U.S, the company’s pricing power has helped maintain its margins. In 2012, for example, Phillip Morris hiked prices on its products in Russia, Germany, Belgium, Canada, France, Greece and Spain, among others. Although the necessary measure caused substantial volume declines in these countries, consumers rapidly became accustomed to the increased prices, and returned to their habitual product consumption. Given the success of this strategy, the firm is likely to rely on it in Japan for 2014, where taxes are expected to increase yet again by 8%, after the 40% spike in October 2010.
Top 5 Safest Stocks To Own For 2015: Pernod Ricard SA (PDRDY)
Pernod Ricard SA is a France-based producer and distributor of spirits and wines. The Company offers such products as whiskies, aniseed spirits, liqueurs, cognacs and brandies, white spirits and rums, bitters, champagnes and wines. Its business is divided into three segments: Top 14 Spirits & Champagne, Priority Premium Wines and 18 key local spirits brands. Pernod Ricard SA’s flagship brands include ABSOLUT, Ricard, Havana Club, Ballantine’s, Malibu, The Glenlivet, Chivas Regal, Beefeater, Kahlua, Martell, Royal Salute, Mumm, Perrier-Jouet and Jameson, among others. The wine category includes, Jacob’s Creek, Brancott Estate, Campo Viejo and Graffigna. It operates as a holding company, with the structure divided between brand owner subsidiaries, such as The Absolut Company, Havana Club International and Chivas Brothers and regional distribution subsidiaries, such as Pernod Ricard Europe, Pernod Ricard Americas and Pernod Ricard Asia, distribute local brands. Advisors’ Opinion:
- [By Charles Sizemore]
But its current valuation—it trades at 31 times earnings—makes me pause. At that price, you are implicitly expecting one of two things to happen:
The American whiskey boom continues unabated for years…and isn’t replaced by something new and trendy. Brown-Forman will be acquired by a larger competitor (think Diageo or Pernod-Ricard (PDRDY)).
The first assumption is one I’d be hesitant to make given the whims of fashion. And the second is even less likely. Brown-Forman is family controlled, and in the past the company has very adamant about preserving its independence.